- Moderna (NASDAQ:MRNA) is planning to file for the approval of the Japanese health ministry’s approval for its COVID-19 vaccine as early as Friday, Kyodo News has reported.
- The filing with Takeda Pharmaceutical (NYSE:TAK), the company’s partner in Japan for handling regulatory clearances and vaccine distribution is the third such application in the country by a vaccine developer after AstraZeneca and Pfizer/BioNTech.
- Japan has already started its vaccination drive with the Pfizer/ BioNTech COVID-19 vaccine.
- In February, it was reported that Takeda had completed the enrollment in Japan of a Phase 1/2 clinical trial for the COVID-19 vaccine candidate (TAK-919) from Moderna.